<article id="navigation_real_world" class="slide" data-ag-name="Real World Navigation">
  <div class="tab-title">wAMD</div>
	<h2 class="slide-title">EFFICACY FROM RANDOMIZED CLINICAL VIEW <br>TRIALS WAS SUPPORTED IN REAL WORLD PRACTICE<sup class="footnote-link">7</sup></h2>
  
  <h3 class="slide-subtitle">THE DESIGN OF A UK MEDISOFT REAL-WORLD EVIDENCE STUDY: TALKS, ET AL.</h3>
  <div class="text">
    <p>Talks, et al. published results from a retrospective real-world study analyzing visual acuity outcomes with EYLEA<sup class="reg">&reg;</sup> 
    <br>from UK electronic medical records containing 1,682 data sets of patients treated for wet AMD. The data set was defined prospectively before first data entry.</p>
  </div>

  <div class="further-details plain">
    <p>Treatment dosage was 2 mg every 2 months (after 3 initial monthly doses) â€“ the mean age of the study population was 80 years</p>
    <span class="parallelogram"></span>
  </div>

  <ul id="secondary-nav" class="navigation-menu">
    <li class="link-slide" data-slideshow="real_world" data-slide="real_world_acuity">
      <h4>
        <span class="link-text">Visual Acuity</span>
        <span class="parallelogram"></span>
      </h4>
    </li>
    <li class="link-slide" data-slideshow="real_world" data-slide="real_world_injections">
      <h4>
        <span class="link-text">Mean Injections</span>
        <span class="parallelogram"></span>
      </h4>
    </li>
  </ul>
</article>